Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 10/7/26 | MimiVax | SurVaxM for Brain Cancer (Malignant Glioma; AA and glioblastoma) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/5/26 | Genmab (GMAB) | Epkinly for Diffuse Large B-Cell Lymphoma (DLBCL) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/1/26 | AbbVie (ABBV) | Rinvoq for Vitiligo | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/1/26 | Boehringer Ingelheim | survodutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/1/26 | Boehringer Ingelheim | survodutide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - sNDA/sBLA Filing |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/13/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |